PeptiDream Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 763

Employees

  • Stock Symbol
  • 4587

Stock Symbol

  • Investments
  • 11

  • Share Price
  • $6.82
  • (As of Monday Closing)

PeptiDream General Information

Description

PeptiDream Inc is engaged in the drug discovery and development business. The group utilizes PDPS, its proprietary drug discovery and development platform system, for drug discovery and development, and it conducts radiopharmaceutical business through a wholly owned subsidiary and is involved in the research, development, and manufacturing of pharmaceuticals, etc. Its reportable segments are Drug discovery and development business and Radiopharmaceutical business.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3-25-23 Tonomachi
  • Kawasaki-ku
  • Kawasaki, Kanagawa 210-0821
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
TKS
Vertical(s)
Corporate Office
  • 3-25-23 Tonomachi
  • Kawasaki-ku
  • Kawasaki, Kanagawa 210-0821
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PeptiDream Stock Performance

As of 16-Nov-2026, PeptiDream’s stock price is $6.82. Its current market cap is $876M with 129M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.82 $6.66 $5.63 - $11.47 $876M 129M 801K -$0.14

PeptiDream Financials Summary

As of 30-Sep-2026, PeptiDream has a trailing 12-month revenue of $130M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 859,125 1,289,379 1,979,919 1,401,863
Revenue 130,154 123,749 308,201 204,342
EBITDA (11,549) (19,563) 154,409 62,975
Net Income (18,391) (25,050) 99,142 21,606
Total Assets 451,995 492,455 590,777 492,548
Total Debt 95,519 108,942 125,036 157,560
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PeptiDream Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PeptiDream‘s full profile, request access.

Request a free trial

PeptiDream Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
PeptiDream Inc is engaged in the drug discovery and development business. The group utilizes PDPS, its proprietary drug
Drug Discovery
Kawasaki, Japan
763 As of 2026

Osaka, Japan
 

Newark, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PeptiDream Competitors (43)

One of PeptiDream’s 43 competitors is AnGes, a Formerly VC-backed company based in Osaka, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnGes Formerly VC-backed Osaka, Japan
Protagonist Therapeutics Formerly VC-backed Newark, CA
Praxis (Drug Discovery) Formerly VC-backed Boston, MA
Axsome Therapeutics Formerly VC-backed New York, NY
Alivexis Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 43 competitors. Get the full list »

PeptiDream Patents

PeptiDream Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026211868-A1 Agent for improving characteristics of peptide, and α-glucosidase Pending 31-Mar-2025
WO-2026205491-A1 Peptide, peptide complex, pharmaceutical composition, composition for cell culture, and composition for medical, diagnostic, or research use Pending 28-Mar-2025
WO-2026127086-A1 Drug Pending 11-Dec-2024
WO-2026128539-A1 Glypican-3 targeting compositions and uses thereof Pending 11-Dec-2024
WO-2026121297-A1 Conjugate comprising peptide and payload Pending 04-Dec-2024
To view PeptiDream’s complete patent history, request access »

PeptiDream Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PeptiDream Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PeptiDream‘s full profile, request access.

Request a free trial

PeptiDream Investments & Acquisitions (11)

PeptiDream’s most recent deal was a Early Stage VC with LinkMed for . The deal was made on 09-Apr-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
LinkMed 09-Apr-2025 Early Stage VC Drug Discovery
LinkMed 22-Dec-2023 Early Stage VC Drug Discovery
PDR Pharma Co. 28-Mar-2022 Merger/Acquisition Drug Discovery
Peptiaid 01-Oct-2020 Joint Venture Drug Discovery
PeptiGrowth 01-Apr-2020 Joint Venture Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 11 investments and acquisitions. Get the full list »

PeptiDream ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

22.72 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view PeptiDream’s complete esg history, request access »

PeptiDream Exits (1)

PeptiDream’s most recent exit was on 13-Nov-2018 from Kleo Pharmaceuticals. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Kleo Pharmaceuticals 13-Nov-2018 Completed
  • 2 buyers
To view PeptiDream’s complete exits history, request access »

PeptiDream Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Peptiaid Kawasaki City, Japan 2020
Pdradiopharma Tokyo, Japan

PeptiDream FAQs

  • When was PeptiDream founded?

    PeptiDream was founded in 2006.

  • Where is PeptiDream headquartered?

    PeptiDream is headquartered in Kawasaki, Japan.

  • What is the size of PeptiDream?

    PeptiDream has 763 total employees.

  • What industry is PeptiDream in?

    PeptiDream’s primary industry is Drug Discovery.

  • Is PeptiDream a private or public company?

    PeptiDream is a Public company.

  • What is PeptiDream’s stock symbol?

    The ticker symbol for PeptiDream is 4587.

  • What is the current stock price of PeptiDream?

    As of 16-Nov-2026 the stock price of PeptiDream is $6.82.

  • What is the current market cap of PeptiDream?

    The current market capitalization of PeptiDream is $876M.

  • What is PeptiDream’s current revenue?

    The trailing twelve month revenue for PeptiDream is $130M.

  • Who are PeptiDream’s competitors?

    AnGes, Protagonist Therapeutics, Praxis (Drug Discovery), Axsome Therapeutics, and Alivexis are some of the 43 competitors of PeptiDream.

  • What is PeptiDream’s annual earnings per share (EPS)?

    PeptiDream’s EPS for 12 months was -$0.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process